Free tool
FAERS Monitor: Monoferric
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208171 or its brand name (Monoferric, Ferric Derisomaltose). Reports on generic versions are filed under their own applications.
Reports
1,366
Serious
726
53% of reports
Hospitalization
230
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea288
- nausea162
- flushing157
- chest discomfort150
- back pain127
- infusion related reaction104
- dizziness100
- vomiting92
- pruritus90
- chest pain87
- abdominal pain74
- hypersensitivity69
- rash67
- hypertension64
- hyperhidrosis63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2020 | 6 |
| 2021 | 153 |
| 2022 | 189 |
| 2023 | 269 |
| 2024 | 272 |
| 2025 | 282 |
| 2026 | 194 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,793 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 104 | 24.2 | 20.1 | 2,293 |
| flushingSignal | 157 | 23.8 | 20.6 | 3,420 |
| chest discomfortSignal | 150 | 22.6 | 19.4 | 3,083 |
| back painSignal | 127 | 8.4 | 7.1 | 832 |
| dyspnoeaSignal | 288 | 7.8 | 7.1 | 1,757 |
| hyperhidrosisSignal | 63 | 7.5 | 5.9 | 352 |
| chest painSignal | 87 | 7.2 | 5.9 | 465 |
| hypersensitivitySignal | 69 | 5.7 | 4.5 | 267 |
| abdominal painSignal | 74 | 4.9 | 3.9 | 228 |
| hypertensionSignal | 64 | 4.7 | 3.7 | 182 |
| pruritusSignal | 90 | 3.6 | 3.0 | 170 |
| nauseaSignal | 162 | 3.2 | 2.7 | 245 |
| dizzinessSignal | 100 | 3.1 | 2.6 | 142 |
| vomitingSignal | 92 | 3.0 | 2.5 | 125 |
| rashSignal | 67 | 2.4 | 1.9 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.